Read by QxMD icon Read

meningococcal b vaccine

Clio A Andreae, Richard B Sessions, Mumtaz Virji, Darryl J Hill
Neisseria meningitidis is an antigenically and genetically variable Gram-negative bacterium and a causative agent of meningococcal meningitis and septicaemia. Meningococci encode many outer membrane proteins, including Opa, Opc, Msf, fHbp and NadA, identified as being involved in colonisation of the host and evasion of the immune response. Although vaccines are available for the prevention of some types of meningococcal disease, none currently offer universal protection. We have used sequences within the Neisseria PubMLST database to determine the variability of msf and opc in 6,500 isolates...
2018: PloS One
A W Dretler, N G Rouphael, D S Stephens
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines...
March 15, 2018: Human Vaccines & Immunotherapeutics
Francelena de Sousa Silva, Yonna Costa Barbosa, Mônica Araújo Batalha, Marizélia Rodrigues Costa Ribeiro, Vanda Maria Ferreira Simões, Maria Dos Remédios Freitas Carvalho Branco, Érika Bárbara Abreu Fonseca Thomaz, Rejane Christine de Sousa Queiroz, Waleska Regina Machado Araújo, Antônio Augusto Moura da Silva
This study estimated the percentages of incomplete immunization with new vaccines and old vaccines and associated factors in children 13 to 35 months of age belonging to a birth cohort in São Luís, the capital of Maranhão State, Brazil. The sample was probabilistic, with 3,076 children born in 2010. Information on vaccination was obtained from the Child's Health Card. The new vaccines, namely those introduced in 2010, were meningococcal C and 10-valent pneumococcal, and the old vaccines, or those already on the childhood immunization schedule, were BCG, hepatitis B, human rotavirus, polio, tetravalent (diphtheria, tetanus, pertussis, Haemophilus influenzae b), yellow fever, and triple viral (measles, mumps, rubella)...
March 12, 2018: Cadernos de Saúde Pública
S Hollingshead, I Jongerius, R M Exley, S Johnson, S M Lea, C M Tang
There is an urgent need to develop vaccines against pathogenic bacteria. However, this is often hindered by antigenic diversity and difficulties encountered manufacturing membrane proteins. Here we show how to use structure-based design to develop chimeric antigens (ChAs) for subunit vaccines. ChAs are generated against serogroup B Neisseria meningitidis (MenB), the predominant cause of meningococcal disease in wealthy countries. MenB ChAs exploit factor H binding protein (fHbp) as a molecular scaffold to display the immunogenic VR2 epitope from the integral membrane protein PorA...
March 13, 2018: Nature Communications
Lisa K McNeil, Robert G K Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L Harris, Thomas R Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W Mayer, Michael W Pride, Kathrin U Jansen, Annaliesa S Anderson
Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories...
March 13, 2018: MBio
Domenico Martinelli, Francesca Fortunato, Stefania Iannazzo, Maria Giovanna Cappelli, Rosa Prato
Background: Vaccine-preventable diseases among high-risk patients are a public health priority in high-income countries. Most national immunization programs have included vaccination recommendations for these population groups but they remain hard-to-reach and coverage data are poorly available. In a pilot study, we developed and tested an automated approach for identifying individuals with underlying medical conditions to feed an immunization information system (IIS). Methods: We reviewed published recommendations on medical conditions that indicate vaccination against influenza, pneumococcal disease, meningococcal disease, hepatitis A, and hepatitis B...
2018: Frontiers in Public Health
Sandra Manzanares-Laya, Oleguer Parés-Badell, Pilar Gorrindo, Pere Simón, Miriam Ros, Anna de Andrés, Núria López Segura, Sonia Brió Sanagustín, Anna Vilella, Carlos Rodrigo Gonzalo de Liria, Àngels Orcau, Joan A Caylà
INTRODUCTION AND OBJECTIVE: The purpose of this study was to describe the evolution of meningococcal disease (MD) in the city of Barcelona between 1988 and 2015 and to assess the impact of the vaccine against serogroup C. MATERIALS AND METHODOLOGY: The evolution of MD and by serogroup was analysed using the information included in the mandatory notification diseases registry. Incidences of all serogroups between the periods of before and after the implementation of the serogroup C vaccine in 2000 were compared...
March 1, 2018: Medicina Clínica
M Giuliani, E Bartolini, B Galli, L Santini, P Lo Surdo, F Buricchi, M Bruttini, B Benucci, N Pacchiani, L Alleri, D Donnarumma, W Pansegrau, I Peschiera, I Ferlenghi, R Cozzi, N Norais, M M Giuliani, D Maione, M Pizza, R Rappuoli, O Finco, V Masignani
4CMenB is the first broad coverage vaccine for the prevention of invasive meningococcal disease caused by serogroup B strains. To gain a comprehensive picture of the antibody response induced upon 4CMenB vaccination and to obtain relevant translational information directly from human studies, we have isolated a panel of human monoclonal antibodies from adult vaccinees. Based on the Ig-gene sequence of the variable region, 37 antigen-specific monoclonal antibodies were identified and produced as recombinant Fab fragments, and a subset also produced as full length recombinant IgG1 and functionally characterized...
February 27, 2018: Scientific Reports
Bahaa Abu Raya, Manish Sadarangani
Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children <2 years of age, and in particular young infants. Vaccination during pregnancy has been a successful strategy for prevention of other infections in young infants, most notably tetanus, pertussis and influenza. However, few studies of meningococcal vaccines in pregnancy have been undertaken, and none include the most commonly used current vaccines to prevent disease by capsular groups A, B, C, W and Y...
February 27, 2018: Human Vaccines & Immunotherapeutics
Jessica Healy, Alfonso Rodriguez-Lainz, Laurie D Elam-Evans, Holly A Hill, Sarah Reagan-Steiner, David Yankey
BACKGROUND: An overall increase has been reported in vaccination rates among adolescents during the past decade. Studies of vaccination coverage have shown disparities when comparing foreign-born and U.S.-born populations among children and adults; however, limited information is available concerning potential disparities in adolescents. METHODS: The National Immunization Survey-Teen is a random-digit-dialed telephone survey of caregivers of adolescents aged 13-17 years, followed by a mail survey to vaccination providers that is used to estimate vaccination coverage among the U...
February 23, 2018: Vaccine
Joan L Robinson
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine...
February 2018: Paediatrics & Child Health
Alicia Arnott, Penelope Jones, Lucinda J Franklin, Denis Spelman, Karin Leder, Allen C Cheng
Background: Overwhelming post-splenectomy infection (OPSI) is a serious complication of asplenia. Clinical guidelines recommend a number of measures to reduce the risk of OPSI, but awareness and adherence to preventative measures is generally poor. We aimed to determine whether a registry for asplenic/hyposplenic patients was associated with a reduction in the incidence of infection with encapsulated bacteria. Methods: We performed a retrospective cohort study of asplenic/hyposplenic patients in the state of Victoria, Australia who registered with Spleen Australia from 2003 - 2014...
February 17, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Dev Chahal, Maria Aleshin, Mamina Turegano, Melvin Chiu, Scott Worswick
BACKGROUND: Erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are cutaneous hypersensitivityreactions that develop in response to specific triggers such as medications and certain infections. Vaccines, which undergo rigorous safety testing prior to use in humans, are a rare cause of SJS/TEN and little is known about the frequency of such events and corresponding pathogenesis. OBJECTIVE: Herein, we discuss a case of suspected TEN in a 19-year-old woman who received the meningococcal B vaccine (the first report of such an association) and conduct a systematic review of the associated literature...
January 15, 2018: Dermatology Online Journal
Kevin L Winthrop, Xavier Mariette, Jose T Silva, Esther Benamu, Leonard H Calabrese, Alexandre Dumusc, Josef S Smolen, José María Aguado, Mario Fernández-Ruiz
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 12, 2018: Clinical Microbiology and Infection
Saad B Omer, Dayna R Clark, Anushka R Aqil, Milagritos D Tapia, Marta C Nunes, Naoko Kozuki, Mark C Steinhoff, Shabir A Madhi, Niteen Wairagkar
BACKGROUND: To evaluate the effect of antenatal influenza vaccination on all-cause severe infant pneumonia, we performed pooled analysis of three randomized-controlled trials conducted in Nepal, Mali, and South Africa. METHODS: The trials were coordinated from the planning phase. The follow-up period was 0-6 months post-partum in Nepal and Mali, and 0-24 weeks in South Africa. Pregnant women with gestational age 17-34 weeks in Nepal, ≥28 weeks in Mali, and 20-36 weeks in South Africa were enrolled...
February 13, 2018: Pediatric Infectious Disease Journal
Gianmarco Ventura, Vincenzo Restivo, Claudio Costantino, Nicolò Casuccio, Claudio D'Angelo, Paola Stefanelli, Alessandra Casuccio, Francesco Vitale
Following two invasive meningococcal disease cases among twenties, general population overloaded vaccination Units of the Palermo's District during summer 2016. Sicilian Health Authorities adopted several public health strategies including: a) active meningococcal vaccination free of charge for people from 18 up to 30 years of age, b) information in crowded places and rapid communication by media. An increase in anti-meningococcal vaccination doses administered (+868%) as well as in anti-dTp and HPV vaccination (+41% and +8%, respectively) due to a further catch-up was observed...
September 2017: Igiene e Sanità Pubblica
Chiara De Waure, Leuconoe Grazia Sisti, Andrea Poscia, Walter Ricciardi
Italy is witnessing relevant challenges in the field of prevention and control of vaccine-preventable diseases. The worrying and growing phenomenon of "vaccine-hesitancy" has contributed to the reduction of vaccination coverage, undermining goals reached thanks to vaccines introduction. The new Italian National Immunization Plan (NIP) 2017-2019 and the update of the list of Essential Care Levels (LEA), approved in the current year, extend the vaccination offer based on the latest scientific evidence with the introduction of new vaccines and the enlargement of target population...
September 2017: Igiene e Sanità Pubblica
Patrizio Pezzotti, Stefania Bellino, Francesca Prestinaci, Simone Iacchini, Francesca Lucaroni, Laura Camoni, Maria Maddalena Barbieri, Walter Ricciardi, Paola Stefanelli, Giovanni Rezza
BACKGROUND: Vaccination has determined a dramatic decline in morbidity and mortality from infectious diseases over the last century. However, low perceived risk of the infectious threat and increased concern about vaccines' safety led to a reduction in vaccine coverage, with increased risk of disease outbreaks. METHODS: Annual surveillance data of nationally communicable infectious diseases in Italy between 1900 and 2015 were used to derive trends in morbidity and mortality rates before and after vaccine introduction, focusing particularly on the effect of vaccination programs...
March 7, 2018: Vaccine
Rolando Felipe Ochoa-Azze
I would like to comment on the article "Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief", DOI: 10.1080/21645515.2017.1381810. The author states that meningococcal group B OMVs vaccines -such as VA-MENGOC-BC®- may induce moderate protection against Neisseria gonorrhoeae. I agree. However, the author states that "there was no evidence of effectiveness in the younger children." The effectiveness of VA-MENGOC-BC® in heterologous contexts has been higher than 80% in individuals older than 4 years old, but the effectiveness in younger children should not be undervalued; it has usually been higher than 60%, and results markedly higher when evaluated based on mortality rates...
February 8, 2018: Human Vaccines & Immunotherapeutics
Jacinto López-Sagaseta, Peter T Beernink, Federica Bianchi, Laura Santini, Elisabetta Frigimelica, Alexander H Lucas, Mariagrazia Pizza, Matthew J Bottomley
Data obtained recently in the United Kingdom following a nationwide infant immunization program against serogroup B Neisseria meningitidis (MenB) reported >80% 4CMenB vaccine-mediated protection. Factor H-binding protein (fHbp) is a meningococcal virulence factor and a component of two new MenB vaccines. Here, we investigated the structural bases underlying the fHbp-dependent protective antibody response in humans, which might inform future antigen design efforts. We present the co-crystal structure of a human antibody Fab targeting fHbp...
February 6, 2018: Nature Communications
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"